Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cytodyn Inc (OP: CYDY ) 0.1455 UNCHANGED Streaming Delayed Price Updated: 3:59 PM EDT, Oct 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Cytodyn Inc < Previous 1 2 3 Next > CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development October 08, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques October 07, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial October 04, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces Preliminary Findings in Study with SMC Laboratories September 24, 2024 From CytoDyn Inc. Via GlobeNewswire September 2024 Letter to Shareholders September 09, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn Engages Leading CRO For Phase II Inflammation Trial August 23, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer August 12, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces Settlement with Amarex Clinical Research LLC July 09, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024 June 27, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn to Host Webcast to Provide Company Update May 28, 2024 From CytoDyn Inc. Via GlobeNewswire May 2024 Letter to Shareholders May 16, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces FDA Has Lifted Clinical Hold February 29, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma February 01, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO January 29, 2024 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces Webcast to Provide Company Update December 07, 2023 From CytoDyn Inc. Via GlobeNewswire CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO November 21, 2023 From CytoDyn Inc. Via GlobeNewswire November 2023 Letter to Shareholders November 03, 2023 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces Company Updates and Investment Community Update Webcast July 11, 2023 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces President Takes Medical Leave of Absence May 24, 2023 From CytoDyn Inc. Via GlobeNewswire CytoDyn to Hold Webcast to Provide a Company Update April 05, 2023 From CytoDyn Inc. Via GlobeNewswire CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO December 23, 2022 From CytoDyn Inc. Via GlobeNewswire CytoDyn to Host R&D Update on Wednesday, December 7, 2022 November 22, 2022 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues October 28, 2022 From CytoDyn Inc. Via GlobeNewswire CytoDyn Announces Appointment of Additional Directors with Industry Experience October 20, 2022 From CytoDyn Inc. Via GlobeNewswire CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm August 11, 2022 From Bragar Eagel & Squire, P.C. Via Business Wire CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm August 10, 2022 From Bragar Eagel & Squire, P.C. Via Business Wire CYTODYN TECHNOLOGIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CytoDyn Inc. - CYDY March 18, 2022 From Kahn Swick & Foti, LLC Via Business Wire CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab January 25, 2022 From CytoDyn Inc. Via Business Wire CytoDyn Cancels Webcast and Live Q/A Scheduled for Today January 13, 2022 From CytoDyn Inc. Via Business Wire Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects January 10, 2022 From CytoDyn Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.